Interestingly, one study have compared clinical outcomes (such as efficacy and adverse events) of two different CD19-tardeted CAR T cells (CD28-based vs. 4-1BB-based CARs) in the patients with B cell non-Hodgkin's lymphoma (B-NHL). The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.